IBRANCE (palbociclib): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

IBRANCE 75 mg 100 mg 125 mg hard capsules

IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:

- in combination with an aromatase inhibitor;

- in combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.


Route of administration: Oral
Molecule: palbociclib

Patients' opinions on IBRANCE

In brief

General satisfaction level: 8.00/10 Learn more

Treatment's effectiveness: 6.00/10 Learn more

Ease of use: 8.00/10 Learn more

Adherence to prescription: 10.00/10 Learn more

Detected side effects: 6.00/10 Learn more

Improvement in the quality of life: 5.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
Carolbreck
on 04/01/2022

Makes you very tired 

Your message

Conditions related to this medication

Fact sheet

Breast cancer

See the fact sheet